PURPOSE: Vatalanib (PTK 787/ZK22584) is an oral poly-tyrosine kinase inhibitor with strong affinity for platelet-derived growth factor and vascular endothelial growth factor (VEGF) receptors. We conducted an open-label, phase II multicenter therapeutic trial investigating the efficacy and tolerability of vatalanib in patients with metastatic or advanced pancreatic cancer who failed first-line gemcitabine-based therapy. METHODS: Vatalanib treatment consisted of a twice daily oral dosing using a "ramp-up schedule," beginning with 250 mg bid during week 1,500 mg bid during week 2, and 750 mg bid on week three and thereafter. The primary objective of this study was to evaluate the 6-month survival rate. RESULTS: Sixty-seven patients were enrolled. The median age was 64, and 66% (N = 43) had only one prior regimen. Common grade 3/4 adverse events included hypertension (20%; N = 13), fatigue (17%; N = 11), abdominal pain (17%; N = 11), and elevated alkaline phosphatase (15%; N = 10). Among the 65 evaluable patients, the 6-month survival rate was 29% (95% CI 18-41%) and the median progression-free survival was 2 months. Fifteen patients survived 6 months or more. Two patients had objective partial responses, and 28% of patients had stable disease. Changes in biomarkers including soluble VEGF and vascular endothelial growth factor receptor did not correlate with response to drug. CONCLUSION: Vatalanib was well tolerated as a second-line therapy and resulted in favorable 6-month survival rate in patients with metastatic pancreatic cancer, compared with historic controls.
PURPOSE:Vatalanib (PTK 787/ZK22584) is an oral poly-tyrosine kinase inhibitor with strong affinity for platelet-derived growth factor and vascular endothelial growth factor (VEGF) receptors. We conducted an open-label, phase II multicenter therapeutic trial investigating the efficacy and tolerability of vatalanib in patients with metastatic or advanced pancreatic cancer who failed first-line gemcitabine-based therapy. METHODS:Vatalanib treatment consisted of a twice daily oral dosing using a "ramp-up schedule," beginning with 250 mg bid during week 1,500 mg bid during week 2, and 750 mg bid on week three and thereafter. The primary objective of this study was to evaluate the 6-month survival rate. RESULTS: Sixty-seven patients were enrolled. The median age was 64, and 66% (N = 43) had only one prior regimen. Common grade 3/4 adverse events included hypertension (20%; N = 13), fatigue (17%; N = 11), abdominal pain (17%; N = 11), and elevated alkaline phosphatase (15%; N = 10). Among the 65 evaluable patients, the 6-month survival rate was 29% (95% CI 18-41%) and the median progression-free survival was 2 months. Fifteen patients survived 6 months or more. Two patients had objective partial responses, and 28% of patients had stable disease. Changes in biomarkers including soluble VEGF and vascular endothelial growth factor receptor did not correlate with response to drug. CONCLUSION:Vatalanib was well tolerated as a second-line therapy and resulted in favorable 6-month survival rate in patients with metastatic pancreatic cancer, compared with historic controls.
Authors: Anne L Thomas; Bruno Morgan; Mark A Horsfield; Anthony Higginson; Andrea Kay; Lucy Lee; Eric Masson; Marie Puccio-Pick; Dirk Laurent; William P Steward Journal: J Clin Oncol Date: 2005-05-02 Impact factor: 44.544
Authors: G Bold; K H Altmann; J Frei; M Lang; P W Manley; P Traxler; B Wietfeld; J Brüggen; E Buchdunger; R Cozens; S Ferrari; P Furet; F Hofmann; G Martiny-Baron; J Mestan; J Rösel; M Sills; D Stover; F Acemoglu; E Boss; R Emmenegger; L Lässer; E Masso; R Roth; C Schlachter; W Vetterli Journal: J Med Chem Date: 2000-06-15 Impact factor: 7.446
Authors: J Drevs; U Zirrgiebel; C I M Schmidt-Gersbach; K Mross; M Medinger; L Lee; J Pinheiro; J Wood; A L Thomas; C Unger; A Henry; W P Steward; D Laurent; D Lebwohl; M Dugan; D Marmé Journal: Ann Oncol Date: 2005-02-10 Impact factor: 32.976
Authors: Bruno Morgan; Anne L Thomas; Joachim Drevs; Juergen Hennig; Martin Buchert; Asvina Jivan; Mark A Horsfield; Klaus Mross; Howard A Ball; Lucy Lee; William Mietlowski; Stefan Fuxuis; Clemens Unger; Ken O'Byrne; Andrew Henry; Graham R Cherryman; Dirk Laurent; Margaret Dugan; Dieter Marmé; William P Steward Journal: J Clin Oncol Date: 2003-09-29 Impact factor: 44.544
Authors: Michele Reni; Stefano Cereda; Michele Milella; Anna Novarino; Alessandro Passardi; Andrea Mambrini; Giuseppe Di Lucca; Giuseppe Aprile; Carmen Belli; Marco Danova; Francesca Bergamo; Enrico Franceschi; Clara Fugazza; Domenica Ceraulo; Eugenio Villa Journal: Eur J Cancer Date: 2013-07-27 Impact factor: 9.162
Authors: Zipeng Lu; Maximilian Weniger; Kuirong Jiang; Stefan Boeck; Kai Zhang; Alexander Bazhin; Yi Miao; Jens Werner; Jan G D'Haese Journal: Target Oncol Date: 2018-08 Impact factor: 4.493
Authors: Jesse Gore; Imade E Imasuen-Williams; Abass M Conteh; Kelly E Craven; Monica Cheng; Murray Korc Journal: Cancer Lett Date: 2016-06-03 Impact factor: 8.679